Myriad Genetics Inc. (MYGN)

28.90
NASDAQ : Health Technology
Prev Close 29.04
Day Low/High 28.72 / 29.37
52 Wk Low/High 17.55 / 41.57
Avg Volume 722.00K
Exchange NASDAQ
Shares Outstanding 69.85M
Market Cap 2.03B
EPS 0.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

Technology Is Fueling Gains: Cramer's 'Mad Money' Recap (Wednesday 4/18/18)

How do you get a stock moving? Jim Cramer says the answer is to invest in technology.

Myriad Receives Pre-Market Approval For Its BRACAnalysis® Diagnostic System In Japan

Myriad Receives Pre-Market Approval For Its BRACAnalysis® Diagnostic System In Japan

Indicated as a Companion Diagnostic for Lynparza® (olaparib) for Use in Patients With Metastatic Inoperable or Recurrent Breast Cancer

Glancy Prongay & Murray LLP Continues Investigation On Behalf Of Myriad Genetics, Inc. Investors (MYGN)

Glancy Prongay & Murray LLP Continues Investigation On Behalf Of Myriad Genetics, Inc. Investors (MYGN)

Glancy Prongay & Murray LLP ("GPM") continues its investigation on behalf of Myriad Genetics, Inc.

INVESTOR ALERT: Kirby McInerney LLP Announces Investigation On Behalf Of Myriad Genetics, Inc. (MYGN) Investors

INVESTOR ALERT: Kirby McInerney LLP Announces Investigation On Behalf Of Myriad Genetics, Inc. (MYGN) Investors

The law firm of Kirby McInerney LLP announced today an investigation on behalf of Myriad Genetics, Inc.

Myriad Applauds AACU Position Statement On Molecular Testing For Risk Stratification In Prostate Cancer

Myriad Applauds AACU Position Statement On Molecular Testing For Risk Stratification In Prostate Cancer

Position Statement Also Supports Access to Hereditary Cancer Testing for Prostate Cancer

Myriad Genetics Demonstrates Strong Commitment To Preventing Hereditary Colon Cancer As Part Of National Colorectal Cancer Awareness Month

Myriad Genetics Demonstrates Strong Commitment To Preventing Hereditary Colon Cancer As Part Of National Colorectal Cancer Awareness Month

Myriad Teams Up with Fight Colorectal Cancer to Support the #StrongArmSelfie Social Media Campaign throughout March

NCCN Guidelines Broadly Endorse Biomarker Testing In Prostate Cancer

NCCN Guidelines Broadly Endorse Biomarker Testing In Prostate Cancer

Prolaris®, myRisk® Hereditary Cancer, and myChoice® HRD Testing Are Appropriate For a Total of 200,000 Prostate Cancer Patients per Year

JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score In Early-Stage Breast Cancer

JAMA Oncology Publication Demonstrates EndoPredict® (EPClin) Significantly Outperforms Oncotype DX® Recurrence Score In Early-Stage Breast Cancer

Large National Payer Expands Coverage Policy to Include EndoPredict for Guiding Extended Hormone Therapy for Patients with ER+ Breast Cancer

Myriad's MyRisk® Hereditary Cancer Test Finds More Than 12 Percent Of Men With Prostate Cancer Carry An Inherited Genetic Mutation

Myriad's MyRisk® Hereditary Cancer Test Finds More Than 12 Percent Of Men With Prostate Cancer Carry An Inherited Genetic Mutation

Results from a Large 1,100 Patient Study Will Be Presented at the 2018 Genitourinary Cancer Symposium

Emerson Electric, S&P Global, Ball Corp.: 'Mad Money' Lightning Round

Emerson Electric, S&P Global, Ball Corp.: 'Mad Money' Lightning Round

Jim Cramer focuses on S&P Global, Myriad Genetics, ProLogis, Emerson Electric, Ball Corp. and more.

Don't Fall for the Downward Bias: Cramer's 'Mad Money' Recap (Thursday, 2/1/18)

Don't Fall for the Downward Bias: Cramer's 'Mad Money' Recap (Thursday, 2/1/18)

Jim Cramer says being a realistic investor doesn't mean being negative, especially when solid reality supports optimism.

Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations For Hereditary Prostate Cancer

Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations For Hereditary Prostate Cancer

Recommends all Metastatic Prostate Cancer Patients Receive Genetic Testing

Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca

Myriad Genetics Announces Expanded Research Collaboration With AstraZeneca

First Phase III PARP Inhibitor Clinical Trial to Use myChoice® HRD Plus as a Potential Companion Diagnostic

First Week of MYGN August 2018 Options Trading

First Week of MYGN August 2018 Options Trading

Investors in Myriad Genetics, Inc. saw new options become available this week, for the August 2018 expiration.

Myriad Genetics Presents Results From Two Important EndoPredict® Studies At The 2017 San Antonio Breast Cancer Symposium

Myriad Genetics Presents Results From Two Important EndoPredict® Studies At The 2017 San Antonio Breast Cancer Symposium

Demonstrates that EndoPredict Predicts Response to Neoadjuvant Therapy in HR+ Breast Cancer

TheStreet Quant Rating: C+ (Hold)